A5012945005- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Peripheral Neuropathies and Disorders
- Immunotherapy and Immune Responses
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Neuroinflammation and Neurodegeneration Mechanisms
- T-cell and Retrovirus Studies
- T-cell and B-cell Immunology
- Mycobacterium research and diagnosis
- Acute Lymphoblastic Leukemia research
- Hereditary Neurological Disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Amyotrophic Lateral Sclerosis Research
- Traumatic Brain Injury and Neurovascular Disturbances
- Systemic Sclerosis and Related Diseases
- Neurosurgical Procedures and Complications
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Neurogenesis and neuroplasticity mechanisms
- Systemic Lupus Erythematosus Research
- HIV Research and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Cerebrospinal fluid and hydrocephalus
- Sphingolipid Metabolism and Signaling
Karolinska Institutet
2016-2025
Danderyds sjukhus
2016-2024
Umeå University
2010-2020
John Wiley & Sons (United States)
2020
Hudson Institute
2020
Karolinska University Hospital
1998-2019
Akershus University Hospital
2019
University of Oslo
2019
University of Gothenburg
1993-2019
Sahlgrenska University Hospital
1990-2019
Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number neurological conditions compared with healthy controls (HC) and candidate biomarker for neuroaxonal damage. The influence age sex largely unknown, levels across disorders have not been systematically to date.
Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable interferon beta and glatiramer acetate (GA), the magnitude potential increase is not well established in real-world populations. Even less known about infection rituximab, which extensively used off-label to treat MS Sweden.To examine serious treatments MS.This nationwide register-based cohort study was conducted Sweden from January 1,...
<h3>Objective:</h3> To examine the effects of disease activity, disability, and disease-modifying therapies (DMTs) on serum neurofilament light (NFL) correlation between NFL concentrations in CSF multiple sclerosis (MS). <h3>Methods:</h3> were measured paired samples (n = 521) from 373 participants: 286 had MS, 45 other neurologic conditions, 42 healthy controls (HCs). In 138 patients with obtained before after DMT treatment a median interval 12 months. The concentration was UmanDiagnostics...
Abstract Objective: The impact of present disease‐modifying treatments (DMTs) in multiple sclerosis (MS) on nerve injury and reactive astrogliosis is still unclear. Therefore, we studied the effect natalizumab treatment release 2 brain‐specific tissue damage markers into cerebrospinal fluid (CSF) MS patients. Methods: CSF samples from 92 patients with relapsing forms were collected a prospective manner prior to after 6 or 12 months. In 86 cases, was used as second‐line DMT due breakthrough...
To investigate the safety and efficacy of rituximab in multiple sclerosis (MS).In this retrospective uncontrolled observational multicenter study, off-label rituximab-treated patients with MS were identified through Swedish register. Outcome data collected from register medical charts. Adverse events (AEs) grades 2-5 according to Common Terminology Criteria for Events recorded.A total 822 identified: 557 relapsing-remitting (RRMS), 198 secondary progressive (SPMS), 67 primary (PPMS). At...
Objective Many JC virus antibody‐positive relapsing–remitting multiple sclerosis (RRMS) patients who are stable on natalizumab switch to other therapies avoid progressive multifocal leukoencephalopathy. Methods We compared outcomes for all RRMS switching from due antibody positivity at 3 Swedish centers with different preferential use of rituximab and fingolimod (Stockholm, n = 156, 51%; Gothenburg, 64, 88%; Umeå, 36, 19%), yielding a total cohort N 256 (fingolimod 55%). Results Within 1.5...
<h3>Importance</h3> Comparative real-world effectiveness studies of initial disease-modifying treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include rituximab are lacking. <h3>Objective</h3> To assess the and drug discontinuation rates among patients with newly diagnosed RRMS compared injectable DMTs, dimethyl fumarate, fingolimod, or natalizumab. <h3>Design, Setting, Patients</h3> This retrospective cohort study used prospectively collected data to examine...
Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary markedly between Denmark and Sweden. The difference in the association of these national with clinical outcomes is unknown.To investigate differences disease-modifying treatment (DMT) RRMS disability outcomes.This cohort study used data on 4861 patients from Danish Swedish (MS) registries date index DMT initiation (between January 1, 2013, December 31, 2016) until last recorded visit at time extraction (October 2,...
In experimental autoimmune encephalomyelitis (EAE), CD4(+) self-reactive T cells target myelin components of the CNS. However, consequences an autoaggressive cell response against for neurons are currently unknown. We herein demonstrate that EAE induced by active immunization with encephalitogenic basic protein peptide dramatically reduces loss spinal motoneurons after ventral root avulsion in rats. Both brain-derived neurotophic factor (BDNF)- and neurotrophin-3 (NT-3)-like...
<b><i>Objective:</i></b> To investigate the association between human herpesviruses and multiple sclerosis (MS), as well measles virus MS. <b><i>Methods:</i></b> The authors identified prospectively collected serum samples from 73 MS cases retrospective sera 161 in two population-based bank registers. Analyses of IgG antibody responses matched referents were performed for Epstein-Barr (EBV [EBNA-1 VCA]), herpesvirus 6 (HHV-6), herpes simplex (HSV), varicella zoster (VZV), measles....
<b><i>Objective:</i></b> To evaluate levels of neurofilament light (NFL) and glial fibrillary acidic protein (GFAP) in CSF from patients with multiple sclerosis (MS) relation to clinical progress the disease. <b><i>Methods:</i></b> NFL GFAP were determined by sensitive ELISAs 99 different subtypes MS, classified terms “ongoing relapse” or “clinically stable disease,” 25 control subjects. Levels compared paraclinical data such as immunoglobulin G index inflammatory cell count CSF, related...
Relapsing-remitting multiple sclerosis has a variable prognosis and lacks reliable laboratory prognostic marker. Our aim in this study was to investigate the association between neurofilament light levels cerebrospinal fluid early disease severity at long-term follow-up. Neurofilament collected diagnostic lumbar puncture were measured 99 cases. Clinical data obtained from 95 out of those follow-up visits made 14 years (range 8—20 years) after onset. Significant correlations score found for...
<h3>Background</h3> Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic sustained follow-up treated patients constitute important information about safety efficacy. In this observational study, we describe the characteristics outcome Swedish with HSCT MS. <h3>Methods</h3> Neurologists major hospitals in Sweden filled out form...
<h3>Objective:</h3> In an ongoing, open-label, phase 1b study on the intrathecal administration of rituximab for progressive multiple sclerosis, intraventricular catheter was inserted drug delivery. The objective this to characterize limited white matter axonal injury evoked by insertion analyzing a panel markers tissue damage in CSF and serum. <h3>Methods:</h3> Lumbar serum were collected before at regular intervals during follow-up period 1 year. Levels neurofilament light polypeptide...
Traumatic brain injury (TBI) is a common cause of death and disability, worldwide. Early determination severity essential to improve care. Neurofilament light (NF-L) has been introduced as marker neuroaxonal in neuroinflammatory/-degenerative diseases. In this study we determined the predictive power serum (s-) cerebrospinal fluid (CSF-) NF-L levels towards outcome, explored their potential correlation diffuse axonal (DAI). A total 182 patients suffering from TBI admitted neurointensive care...
Background: In progressive multiple sclerosis (PMS), disease-modifying therapies have not been shown to reduce disability progression. Objective: The impact from immunosuppressive therapy in PMS was explored by analyzing cerebrospinal fluid (CSF) biomarkers of axonal damage (neurofilament light protein, NFL), astrogliosis (glial fibrillary acidic GFAP), and B-cell regulation (CXCL13). Methods: CSF obtained 35 patients with before after 12–24 months mitoxantrone ( n=30) or rituximab n=5)...
Background Neurofilament light (NFL) and Glial Fibrillary Acidic Protein (GFAP) are integral parts of the axonal astrocytal cytoskeletons respectively released into cerebrospinal fluid (CSF) in cases cellular damage. In order to interpret levels these biomarkers disease states, knowledge on normal healthy is required. Another biomarker for neurodegeneration brain atrophy, commonly measured as parenchymal fraction (BPF) using magnetic resonance imaging (MRI). Potential correlations between...
Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue. Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related The TYNERGY study aimed further evaluate the effects of natalizumab treatment on In this one-armed clinical trial including 195 MS patients, was prescribed real-life setting, and validated questionnaire,...
Novel, highly effective disease-modifying therapies have revolutionized multiple sclerosis (MS) care. However, evidence from large comparative studies on important safety outcomes, such as cancer, is still lacking.In this nationwide register-based cohort study, we linked data the Swedish MS register to Cancer Register and other national health care census registers. We included 4,187 first-ever initiations of rituximab, 1,620 fingolimod, 1,670 natalizumab in 6,136 patients matched for age,...
Background: A post marketing surveillance study was conducted to evaluate safety and efficacy of natalizumab in Swedish multiple sclerosis (MS) patients since its introduction August 2006 until March 2010. Methods: Patients were registered the web-based MS-registry at 40 locations evaluated every 6 months. Adverse events clinical outcomes recorded. Results: One thousand one hundred fifty-two included (71.4% female) 149 stopped treatment; main reason planned pregnancy. Anti-natalizumab...
Inflammatory mediators have crucial roles in leukocyte recruitment and subsequent central nervous system (CNS) neuroinflammation. The extent of neuronal injury axonal loss are associated with the degree CNS inflammation determine physical disability multiple sclerosis (MS). aim this study was to explore possible associations between a panel selected cerebrospinal fluid biomarkers robust clinical demographic parameters large cohort patients MS controls (n = 1066) using data-driven...
<h3>Objective:</h3> To describe the effects of switching treatment from ongoing first-line injectable therapies to rituximab on inflammatory activity measured by MRI and levels CSF neurofilament light chain (CSF-NFL) in a cohort patients with clinically stable relapsing-remitting multiple sclerosis (RRMS). <h3>Method:</h3> Seventy-five RRMS treated injectables interferon-β (IFN-β) glatiramer acetate (GA) at 3 Swedish centers were switched this open-label phase II multicenter study. After...